ArticleCureus2024
The Predictive Role of Maternal Serum Amyloid A in Preterm Birth: An Observational Study in Romania.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Relationship Between Maternal Serum Amyloid A Levels and Neonatal Outcomes in Preterm Births.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite improvements in pregnancy care, preterm birth remains a major cause of neonatal morbidity and mortality worldwide, particularly in developing countries. Maternal inflammation has been recognized as a factor that may induce preterm birth, with various inflammatory markers associated with its pathogenesis. The aim of this study is to evaluate the value of maternal serum amyloid A(SAA) level as a predictive marker for preterm delivery in a Romanian cohort.
methodsThis observational study was carried out at a Romanian tertiary care hospital between April 2023 and March 2024. We enrolled 136 pregnant women and divided them into two groups depending on the beginning of labor: preterm (before 37 weeks, n=70) and term (after 37 weeks, n=66). Maternal blood samples were taken upon admission and analyzed using the Atellica® NEPH 630 System (Siemens Healthineers, Erlangen, Germany) to determine SAA levels. The best cut-off value for SAA was determined using receiver operating characteristic (ROC) curve analysis with the Youden index. Logistic regression models were then applied to assess the association between elevated SAA levels and preterm birth, adjusting for potential confounders such as maternal age and history of preterm birth.
resultsThe median SAA levels were significantly higher in the preterm group (22 mg/L) compared to the term group (7 mg/L) (p<0.001). The ROC curve analysis yielded a moderate predictive value of SAA for preterm birth, with the area under the ROC curve (AUC) being 0.690. The threshold at 15 mg/L was the best cut-off value, achieving a sensitivity of 89% and a specificity of 85%. Elevated SAA levels were associated with a 27.89-fold increased risk of preterm delivery. Further, after adjusting for maternal age, medical conditions during pregnancy, and prior preterm birth, elevated SAA remained a significant predictor of preterm birth (adjusted odds ratio (aOR)=28.966; p=0.001).
conclusionMaternal SAA proved to be a strong independent risk factor for preterm birth. This biomarker further narrows the population of pregnant women at higher risk of preterm delivery and opens new perspectives for its clinical role in preterm birth prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.